Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the <scp>BioDay</scp> registry-Reference-Cited by-同舟云学术

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

Published:2022-12 Issue:12 Volume:33 Page:
ISSN:0905-6157
Container-title:Pediatric Allergy and Immunology
language:en
Short-container-title:Pediatric Allergy Immunology

Author:

Kamphuis Esmé¹^ORCID,Boesjes Celeste M.²^ORCID,Loman Laura¹^ORCID,Bakker Daphne S.²^ORCID,Poelhekken Mila¹^ORCID,Zuithoff Nicolaas P. A.³^ORCID,Kamsteeg Marijke⁴^ORCID,Romeijn Geertruida L. E.¹^ORCID,van Wijk Femke⁵^ORCID,de Bruin‐Weller Marjolein S.²^ORCID,de Graaf Marlies²^ORCID,Schuttelaar Marie L. A.¹^ORCID

Affiliation:

1. Department of Dermatology, University Medical Center Groningen University of Groningen Groningen the Netherlands

2. Department of Dermatology, University Medical Center Utrecht University of Utrecht Utrecht the Netherlands

3. Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht the Netherlands

4. Department of Dermatology, Radboud University Medical Center Radboud University Nijmegen the Netherlands

5. Center for Translational Immunology, University Medical Center Utrecht University of Utrecht Utrecht the Netherlands

Funder

AbbVie

Eli Lilly and Company

LEO Pharma Research Foundation

Pfizer

Sanofi

Publisher

Wiley

Subject

Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pai.13887

Reference29 articles.

1. Atopic dermatitis in the pediatric population

2. IMPACTO DA DERMATITE ATÓPICA NA QUALIDADE DE VIDA DE PACIENTES PEDIÁTRICOS E SEUS RESPONSÁVEIS

3. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

4. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

5. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry;Journal of the American Academy of Dermatology;2024-08

3. Use of Dupilumab in Pediatric Patients: A Review;Current Pediatrics Reports;2024-06-20

4. An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis;Pediatric Allergy and Immunology;2024-06

5. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry;Allergy;2024-05-07